What is PYC Therapeutics?
PYC Therapeutics is a specialized biotechnology firm dedicated to the discovery and development of novel RNA-based therapies. By focusing on high-unmet-need genetic conditions, the company has established a robust portfolio that includes clinical-stage programs such as VP-001 for retinitis pigmentosa type 11 and PYC-001 for Autosomal Dominant Optic Atrophy. Their operational model leverages sophisticated academic-industry collaborations, notably with Murdoch University, to bridge the gap between fundamental research and therapeutic application. This integration of advanced molecular biology and clinical rigor positions PYC Therapeutics as a critical player in the evolving landscape of precision medicine and neurodegenerative disorder management.
How much funding has PYC Therapeutics raised?
PYC Therapeutics has raised a total of $121.6M across 2 funding rounds:
Other Financing Round
$74.6M
Stock/Share Issuance
$47M
Other Financing Round (2024): $74.6M, investors not publicly disclosed
Stock/Share Issuance (2026): $47M, investors not publicly disclosed
Key Investors in PYC Therapeutics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for PYC Therapeutics?
With the recent infusion of capital, PYC Therapeutics is well-positioned to transition its pre-clinical assets, such as PYC-002 for Phelan-McDermid Syndrome, into more advanced clinical phases. The strategic roadmap emphasizes the scaling of its drug discovery engine and the optimization of its proprietary delivery platforms. As the company navigates the complexities of late-stage clinical trials, the focus will remain on achieving regulatory milestones and demonstrating the efficacy of its RNA therapeutics in diverse patient populations. This financial backing serves as a catalyst for long-term growth, enabling the firm to solidify its market presence and potentially redefine the standard of care for patients suffering from rare genetic diseases.
See full PYC Therapeutics company page
